相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe
W. P. C. Boon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Safety-Related Regulatory Actions for Orphan Drugs in the US and EU A Cohort Study
Harald E. Heemstra et al.
DRUG SAFETY (2010)
A Decade of Safety-Related Regulatory Action in the Netherlands A Retrospective Analysis of Direct Healthcare Professional Communications from 1999 to 2009
Peter G. M. Mol et al.
DRUG SAFETY (2010)
New drug approval success rate in Europe in 2009
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
Elizabeth A. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Balancing drug risk and benefit: Toward refining the process of FDA decisions affecting patient care
Lawrence R. Schiller et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands
Anne J. Leendertse et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Safety-related regulatory actions for biologicals approved in the United States and the European Union
Thijs J. Giezen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Drug-review deadlines and safety problems
Daniel Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics
Robert M. Califf
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline
B Darpo et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care
TC Jones
SCIENCE AND ENGINEERING ETHICS (2005)
Connecting pre-marketing clinical research and medical practice - Opinion-based study of core issues and possible changes in drug regulation
NF Wieringa et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2003)
Timing of new black box warnings and withdrawals for prescription medications
KE Lasser et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
